Cholinergic Mechanisms of Attention in Aging
试验速览
- 阶段
- 早期 1 期
- 状态
- 已完成
- 入组人数
- 19
- 试验地点
- 1
- 主要终点
- Proportion of participants who complete EEG
研究概览
简要总结
This study will use an anticholinergic pharmacological probe to examine attention network function in SCD using EEG. The overall hypothesis is that in older adults with SCD, normal cognitive performance is maintained by compensatory attention network activity, supported by enhanced cholinergic function. The investigators anticipate that SCD will be associated with greater compensatory attention network activity and that disrupting this compensatory process through anticholinergic challenge will result in a greater negative effect on attentional performance (Attention Network Test, ANT) and attention network functioning (EEG) in older adults with SCD compared to those without SCD.
详细描述
Overview: Cognitively normal older adults with and without subjective cognitive decline (SCD) (n = 20; SCD = 10, Non-SCD = 10) will complete two study visits that will be double blinded and randomized for anticholinergic challenge (mecamylamine/scopolamine or placebo). Drug challenge visits will include cognitive testing and an electroencephalography (EEG) session.
Aim 1: Feasibility of EEG during mecamylamine/scopolamine challenge
The primary outcome measures for Aim 1 will be the rate of completion of study visits with drug challenge and of completion of EEG tasks during the study visits with drug challenge.
Attention Network Test: The attention network test (ANT) is designed to test selective attention , and combines attentional cues with a flanker task. Behavioral measures of the ANT will be 1) Alerting: reaction time (RT) non-cue trials - cue trials; 2) Orienting: RT neutral cue trials - spatial cue trials; 3) Executive: RT incongruent trials - congruent trials.
EEG, Task-related Event Related Potentials: Each participant will complete the ANT during EEG with primary event relation potential (ERP) measures: 1) Alerting: early sensory ERP (P1) amplitude; 2) Orienting: early sensory ERP (P1) amplitude; 3) Executive: target and conflict evaluation ERP (P3) amplitude. Other ERP signals related to attention and sensory processing will be examined in exploratory analyses.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Basic Science
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 55 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Montreal Cognitive Assessment (MoCA) > 25 AND Global Deterioration Scale (GDS) rating < 3
- •Non-smokers
排除标准
- •medical contraindications to the drug challenge
- •primary neurological disorder (such as stroke, epilepsy, etc.)
研究组 & 干预措施
Anticholinergic Challenge
All participants will receive oral mecamylamine or IV scopolamine for 1 day
干预措施: Mecamylamine Challenge (Drug)
Placebo Challenge
All participants will receive oral placebo for 1 day
干预措施: Placebo Comparator Challenge (Other)
结局指标
主要结局
Proportion of participants who complete EEG
时间窗: After administration of second drug challenge, approximately 72 hours
Proportion of participants who complete EEG sessions as measured by adminstration of EEG
Proportion of participants who complete study visits with drug challenge
时间窗: After administration of second drug challenge, approximately 72 hours
Proportion of particiapnts who complete study days as measured by study drug administration on both study visits with drug challenge
次要结局
未报告次要终点
研究者
Kimberly Albert
Research Instructor, Psychiatry
Vanderbilt University Medical Center